ストックスクリーナーアプリを入手
16.75
15.37%
2.231
プレマーケット:
16.94
0.189
+1.13%
Eyepoint Pharmaceuticals Inc (EYPT) 最新ニュース
Will EyePoint Pharmaceuticals Inc. stock outperform value stocksQuarterly Portfolio Review & AI Powered Trade Plan Recommendations - Newser
How EyePoint Pharmaceuticals Inc. (PV3B) stock responds to job market shiftsJuly 2025 Rallies & Detailed Earnings Play Strategies - Newser
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD - Investing.com
Eyepoint Pharmaceuticals stock hits 52-week high at 15.0 USD By Investing.com - Investing.com Nigeria
Will EyePoint Pharmaceuticals Inc. (PV3B) stock outperform energy sector in 2025CPI Data & Weekly Return Optimization Plans - Newser
How buyback programs support EyePoint Pharmaceuticals Inc. (PV3B) stockJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - Newser
Is EyePoint Pharmaceuticals Inc. (PV3B) stock positioned for secular growthWeekly Earnings Recap & Fast Entry Momentum Alerts - Newser
Can EyePoint Pharmaceuticals Inc. (PV3B) stock deliver strong annual returnsJuly 2025 Drop Watch & Weekly Watchlist for Consistent Profits - Newser
EyePoint Pharmaceuticals: Promising Outlook for Duravyu in Wet AMD Treatment and Strategic Growth Potential - TipRanks
EyePoint Pharmaceuticals Director Sells Shares - TradingView
XTX Topco Ltd Acquires 94,210 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
What drives EyePoint Pharmaceuticals Inc stock priceEvening Star Patterns & Exceptional Return Capital - earlytimes.in
Investors Appear Satisfied With EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Prospects As Shares Rocket 26% - 富途牛牛
EyePoint Pharmaceuticals (EYPT) Is Up 8.4% After Positive Phase 3 Safety Review for DURAVYU - Sahm
Officer/Dir Lurker Files To Sell 500 Of EyePoint Pharmaceuticals Inc [EYPT] - TradingView
What analysts say about EyePoint Pharmaceuticals Inc PV3B stockHigh Dividend Yield Stocks & Access Free Risk Analysis Before You Invest - earlytimes.in
Avoiding Lag: Real-Time Signals in (EYPT) Movement - news.stocktradersdaily.com
EyePoint Pharmaceuticals (EYPT): A Fresh Valuation Look Following Key DURAVYU Phase 3 Safety Review Completion - sahmcapital.com
Will EyePoint Pharmaceuticals Inc. stock see PE expansionJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - BỘ NỘI VỤ
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 By Investing.com - Investing.com Nigeria
Eyepoint Pharmaceuticals stock hits 52-week high at $14.94 - Investing.com
EyePoint receives second consecutive positive recommendation from DSMC - Modern Retina
Why Institutions Believe Infibeam Avenues Limited Is Undervalued TodayStock Watchlist Updates & Collaborate and Win Together - earlytimes.in
EyePoint Pharmaceuticals (EYPT) Clears Phase 3 Safety Hurdle for DURAVYU—Is a New Wet AMD Era Ahead? - sahmcapital.com
Can EyePoint Pharmaceuticals Inc. (PV3B) stock sustain double digit ROETrade Risk Report & Detailed Earnings Play Alerts - newser.com
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock beat growth indexesExit Point & Daily Technical Forecast Reports - newser.com
Is EyePoint Pharmaceuticals Inc. (PV3B) stock trading at attractive multiplesEarnings Risk Summary & Smart Swing Trading Alerts - newser.com
Is EyePoint Pharmaceuticals Inc. stock attractive for passive investorsJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
Why ETFs are accumulating EyePoint Pharmaceuticals Inc. (PV3B) stock2025 Biggest Moves & Free Reliable Trade Execution Plans - newser.com
What margin trends mean for EyePoint Pharmaceuticals Inc. stockForecast Cut & Daily Technical Forecast Reports - newser.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock hit Wall Street targetsQuarterly Earnings Summary & Daily Oversold Bounce Ideas - newser.com
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review - Yahoo Finance
How EyePoint Pharmaceuticals Inc. stock performs in high volatility marketsGold Moves & Precise Entry and Exit Recommendations - newser.com
Is EyePoint Pharmaceuticals Inc. stock ready for breakout2025 Bull vs Bear & Real-Time Volume Analysis - newser.com
Eyepoint Pharmaceuticals secures positive Phase 3 wet AMD trial review - Traders Union
EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee - MarketScreener
EyePoint (EYPT) Receives Green Light to Proceed with Phase 3 DUR - GuruFocus
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):